Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

JRNYS vs Nova MD

JRNYS
Graded #267

Lower grade

vs+4.400000000000006
Nova MD
Graded #174

Higher grade

The verdict

Nova MD takes it — 66.9/100 to 62.5/100.

Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNova MD +23
45
68
Dose & formulationNova MD +6
58
64
Clinical oversightJRNYS +2
84
82
Labs & monitoringJRNYS +17
71
54
FulfillmentNova MD +3
65
68
Contract termsEven
55
55
JRNYS · left barNova MD · right bar

The numbers

MetricJRNYSNova MD
WeighScore62.5/10066.9/100
GradeCC
Scorecard rank#267#174
SemaglutideNot disclosed$175/mo (compounded)
TirzepatideNot disclosed$225/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published
Nova MD

Graded #174 · C

Strengths

  • On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
  • $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
  • $50 off first tirzepatide order shown publicly
  • Explicit microdose / low-dose program for both semaglutide and tirzepatide
  • Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy not named — only 'accredited facilities'
  • LegitScript certification not confirmed (only 'Licensed US Providers' claims)
  • Per-state availability not listed
  • Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard